Cytosorbents Corporation

NasdaqCM:CTSO Stock Report

Market Cap: US$56.9m

Cytosorbents Management

Management criteria checks 2/4

Cytosorbents' CEO is Phil Chan, appointed in Jan 2009, has a tenure of 16.5 years. total yearly compensation is $1.33M, comprised of 36.2% salary and 63.8% bonuses, including company stock and options. directly owns 1.35% of the company’s shares, worth $768.95K. The average tenure of the management team and the board of directors is 4.7 years and 10.3 years respectively.

Key information

Phil Chan

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage36.2%
CEO tenure16yrs
CEO ownership1.4%
Management average tenure4.7yrs
Board average tenure10.3yrs

Recent management updates

Recent updates

The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Oct 01
The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Jul 04
Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13
Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

May 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 08
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents secures $4.3M contract by U.S. Department of Defense

Oct 06

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

CEO Compensation Analysis

How has Phil Chan's remuneration changed compared to Cytosorbents's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$1mUS$483k

-US$29m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$26m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$483k

-US$33m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$483k

-US$25m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$1mUS$456k

-US$8m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$1mUS$438k

-US$19m

Sep 30 2019n/an/a

-US$21m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$1mUS$400k

-US$17m

Compensation vs Market: Phil's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD642.40K).

Compensation vs Earnings: Phil's compensation has increased whilst the company is unprofitable.

CEO

Phil Chan (54 yo)

16yrs

Tenure

US$1,333,402

Compensation

Dr. Phillip P. Chan, M.D., Ph D., is known as Phil has been the Chief Executive Officer at Cytosorbents Corporation since January 2009 and served as its President until May 2020. Dr. Chan serves as a Partn...

Leadership Team

NamePositionTenureCompensationOwnership
Phillip Chan
CEO & Director16yrsUS$1.33m1.35%
$ 768.9k
Vincent Capponi
President & COO19.5yrsUS$1.11m0.51%
$ 292.4k
Kathleen Bloch
Advisorless than a yearUS$816.08k0.54%
$ 306.7k
Efthymios Deliargyris
Chief Medical Officer4.7yrsUS$1.06m0.17%
$ 97.7k
Peter Mariani
Chief Financial Officerless than a yearno data0.094%
$ 53.4k
Terri Powers
Vice President of Investor Relations & Corporate Communications3.6yrsno datano data
Christian Steiner
Executive Vice President of Sales & Marketing12.6yrsno datano data
Christopher Cramer
Senior Vice President of Business Development2yrsno datano data
Jodi Hoover
Executiveno datano datano data
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant7.6yrsUS$97.32kno data

4.7yrs

Average Tenure

63yo

Average Age

Experienced Management: CTSO's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Phillip Chan
CEO & Director16.5yrsUS$1.33m1.35%
$ 768.9k
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant10.3yrsUS$97.32kno data
Claudio Ronco
Member of Critical Care Advisory Boardno datano datano data
Alan Sobel
Independent Director10.2yrsUS$118.47k0.063%
$ 35.9k
Edward Jones
Independent Director17.8yrsUS$101.93k0.036%
$ 20.3k
Joseph Parrillo
Member of Critical Care Advisory Boardno datano datano data
Ronald Maier
Chairman of the Trauma Advisory Board11.8yrsno datano data
Mitchell Cohen
Member of Trauma Advisory Boardno datano datano data
Ernest Moore
Member of Trauma Advisory Board11.8yrsno datano data
Joseph Zwischenberger
Chairman of Cardiac Surgery Advisory Board10.3yrsno datano data
Jonathan Haft
Member of Cardiac Surgery Advisory Board10.3yrsno datano data
Michael Bator
Independent Chairman of the Board9.5yrsUS$161.70k0.10%
$ 58.3k

10.3yrs

Average Tenure

63yo

Average Age

Experienced Board: CTSO's board of directors are seasoned and experienced ( 10.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 06:34
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cytosorbents Corporation is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffBrean Capital
Jason KolbertD. Boral Capital LLC.
Swayampakula RamakanthH.C. Wainwright & Co.